1. Market Research
  2. > ERYtech Pharma - Product Pipeline Review - 2013

ERYtech Pharma - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

ERYtech Pharma - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “ERYtech Pharma - Product Pipeline Review - 2013” provides data on the ERYtech Pharma’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ERYtech Pharma’s corporate website, SEC filings, investor presentations and featured press releases, both from ERYtech Pharma and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- ERYtech Pharma - Brief ERYtech Pharma overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ERYtech Pharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ERYtech Pharma with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ERYtech Pharma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate ERYtech Pharma’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ERYtech Pharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ERYtech Pharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ERYtech Pharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ERYtech Pharma and identify potential opportunities in those areas.

Table Of Contents

ERYtech Pharma - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
ERYtech Pharma Snapshot 4
ERYtech Pharma Overview 4
Key Information 4
Key Facts 4
ERYtech Pharma - Research and Development Overview 5
Key Therapeutic Areas 5
ERYtech Pharma - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
ERYtech Pharma - Pipeline Products Glance 9
ERYtech Pharma - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
ERYtech Pharma Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
ERYtech Pharma - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
ERYtech Pharma - Drug Profiles 13
asparaginase 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Enhoxy 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ERYGEN 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
ERYtech Pharma - Pipeline Analysis 17
ERYtech Pharma - Pipeline Products by Therapeutic Class 17
ERYtech Pharma - Pipeline Products by Route of Administration 18
ERYtech Pharma - Pipeline Products By Mechanism of Action 19
ERYtech Pharma - Recent Pipeline Updates 20
ERYtech Pharma - Dormant Projects 22
ERYtech Pharma - Locations And Subsidiaries 23
Head Office 23
Other Locations and Subsidiaries 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables


ERYtech Pharma, Key Information 4
ERYtech Pharma, Key Facts 4
ERYtech Pharma - Pipeline by Indication, 2013 6
ERYtech Pharma - Pipeline by Stage of Development, 2013 7
ERYtech Pharma - Monotherapy Products in Pipeline, 2013 8
ERYtech Pharma - Phase III, 2013 9
ERYtech Pharma - Phase II, 2013 10
ERYtech Pharma - Phase I, 2013 11
ERYtech Pharma - Pre-Clinical, 2013 12
ERYtech Pharma - Pipeline By Therapeutic Class, 2013 17
ERYtech Pharma - Pipeline By Route of Administration, 2013 18
ERYtech Pharma - Pipeline Products By Mechanism of Action, 2013 19
ERYtech Pharma - Recent Pipeline Updates, 2013 20
ERYtech Pharma - Dormant Developmental Projects,2013 22
ERYtech Pharma, Other Locations 23

List of Figures


ERYtech Pharma - Pipeline by Indication, 2013 6
ERYtech Pharma - Pipeline by Stage of Development, 2013 7
ERYtech Pharma - Monotherapy Products in Pipeline, 2013 8
ERYtech Pharma - Pipeline By Therapeutic Class, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.